Skip to content

Study on the establishment and verification of prognostic prediction model based on MEST-C pathological score and multiple biomarkers in IgA nephropathy

Study on the establishment and verification of prognostic prediction model based on MEST-C pathological score and multiple biomarkers in IgA nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044749
Enrollment
Unknown
Registered
2021-03-26
Start date
2021-03-26
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

High-risk group VS low-risk group:Nil

Sponsors

Yuebei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed IgAN patients diagnosed by renal pathology; 2.First visit eGFR >= 30 ml/(min·1.73 m2); 3.Proteinuria >= 0.5g/24 h (>= 0.5 g/(24h·1.73 m2) in minors); 4.The follow-up time exceeds 12 months; 5.Peripheral blood samples and pathological biopsy samples at the time of initial diagnosis are available.

Exclusion criteria

Exclusion criteria: 1.Patients who have been treated with glucocorticoids or other immunosuppressive agents when they were first admitted to the hospital; 2.Patients with missing baseline data at the first visit; 3.Patients with hematological system or solid tumors, serious infections and other major complications that may affect the research.

Design outcomes

Primary

MeasureTime frame
eGFR;ESRD;

Secondary

MeasureTime frame
AUC;Sensitivity and Specificity;

Countries

China

Contacts

Public ContactHe Min

Department of Nephrology, Yuebei People's Hospital

minhe20030701@163.com+86 13680069382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026